2060 results about "Co solvent" patented technology

A well treatment microemulsion for use in a subterranean formation is disclosed, the microemulsion comprises a solvent blend comprising a solvent and a co-solvent; a surfactant blend comprising a surfactant, wherein the surfactant blend is able to give formation intermediate wettability properties; an alcohol; and a carrier fluid; wherein the alcohol, the solvent and surfactant blends are combined with the carrier fluid to produce the well treatment microemulsion. By intermediate wettability it is meant that the water has an advancing contact angle on the surface between 62 and 133 degrees. The associate method of treating a subterranean formation of a well with the microemulsion and the associate method of modifying the wettability of the formation with the microemulsion are also disclosed.

The present invention relates to nano-sized self-assembled structured concentrates and their use as effective suitable carriers for transferring active components into the human body. The nano-sized self-assembled concentrates are composed of an aqueous phase, an oil phase, a surfactant a co-solvent and co-surfactant. The formed nano-sized self-assembled structured concentrates may be in the form of an aqueous continuous phase, an oil continuous phase or a bicontinuous phase, and may thus be diluted to any desired extent in either oil or water maintaining their structure and the active material comprised within the nano-sized self-assembled structured concentrates.

A microemulsion system is disclosed which comprises a solvent subsystem, a co-solvent subsystem and a surfactant subsystem comprises at least one monoalkyl branched propoxy sulfate anionic surfactant, where the microemulsion system are useful in drilling, producing, remediation, and fracturing application to reduce water blocks and water blocking in formation of a producing formation.

The present invention relates to a foamable therapeutic composition comprising: (a) a therapeutically effective concentration of at least one active agent selected from the group consisting of a channel agent, a cholinergic agent, and a nitric oxide donor; and (b) a foamable carrier comprising:i. about 50% to about 98% of a solvent selected from the group consisting of water; a hydrophilic solvent; a hydrophobic solvent; a potent solvent; a polar solvent, a silicone, an emollient, and mixtures thereof;ii. 0% to about 48% of a secondary solvent selected from the group consisting of water; a hydrophilic solvent; a hydrophobic solvent; a potent solvent; a polar solvent, a silicone, an emollient, a co-solvent, a penetration enhancer and mixtures thereof;iii. a surface-active agent;iv. about 0% to about 5% by weight of at least one polymeric agent; andv. a liquefied or compressed gas propellant at a concentration of about 3% to about 25% by weight of the total composition;wherein the composition is housed in a container and is substantially flowable, andwhich upon release expands to form a breakable foam; andwherein the foamable carrier is selected to generate a foam of good to excellent quality.The invention further provides a method of treating, alleviating or preventing a disorder of mammalian subject, comprising administering such a composition to an afflicted target site.

A stable topical alcohol-free aerosol foam containing one or more keratolytic agents is provided. The foam-forming formulation is an oil-in-water emulsion which contains one or more hydrofluoroalkane (HFA) propellants and one or more keratolytic agents. The keratolytic agent may be present in either phase of the emulsion or dispersed in the emulsion. The oil phase may consist at least in part of the HFA propellant. The foam is stable on the skin for at least 5 minutes at body temperature and disappears into the skin upon rubbing or after prolonged standing. The formulations may not contain additional co-solvents or non-HFA co-propellants. The formulations demonstrate reduced intensity of the odor and / or color associated with the keratolytic agent(s) as compared to conventional formulations containing keratolytic agents.